OBJECTIVE: To provide a reference to rheumatologists and to those involved in the treatment of RA who are using, or about to use biologic therapy. METHODS: Recommendations were developed following a nominal group methodology and based on systematic reviews. The level of evidence and grade of recommendation were classified according to the model proposed by the Center for Evidence Based Medicine at Oxford. The level of agreement was established through Delphi technique. RESULTS: We have produced recommendations on the use of the seven biologic agents available for RA in our country. The objective of treatment is to achieve the remission of the disease as quickly as possible. Indications and nuances regarding the use of biologic therapy were reviewed as well as the evaluation that should be performed prior to administration and the follow up of patients undergoing this therapy. CONCLUSIONS: We present an update on the SER recommendations for the use of biologic therapy in patients with RA.
OBJECTIVE: To provide a reference to rheumatologists and to those involved in the treatment of RA who are using, or about to use biologic therapy. METHODS: Recommendations were developed following a nominal group methodology and based on systematic reviews. The level of evidence and grade of recommendation were classified according to the model proposed by the Center for Evidence Based Medicine at Oxford. The level of agreement was established through Delphi technique. RESULTS: We have produced recommendations on the use of the seven biologic agents available for RA in our country. The objective of treatment is to achieve the remission of the disease as quickly as possible. Indications and nuances regarding the use of biologic therapy were reviewed as well as the evaluation that should be performed prior to administration and the follow up of patients undergoing this therapy. CONCLUSIONS: We present an update on the SER recommendations for the use of biologic therapy in patients with RA.
Authors: José Andrés Román Ivorra; Juan Antonio Martínez; Pablo Lázaro; Federico Navarro; Antonio Fernandez-Nebro; Eugenio de Miguel; Estibaliz Loza; Loreto Carmona Journal: Rheumatol Int Date: 2013-04-09 Impact factor: 2.631
Authors: Isidoro González-Álvaro; Ana M Ortiz; José María Alvaro-Gracia; Santos Castañeda; Belen Díaz-Sánchez; Inmaculada Carvajal; J Alberto García-Vadillo; Alicia Humbría; J Pedro López-Bote; Esther Patiño; Eva G Tomero; Esther F Vicente; Pedro Sabando; Rosario García-Vicuña Journal: PLoS One Date: 2011-12-29 Impact factor: 3.240
Authors: Javier Narváez; César Díaz-Torné; Berta Magallares; Maria Victoria Hernández; Delia Reina; Héctor Corominas; Raimon Sanmartí; Arturo Rodriguez de la Serna; Josep Maria Llobet; Joan M Nolla Journal: PLoS One Date: 2015-04-01 Impact factor: 3.240
Authors: Mario Gil-Conesa; Juan Antonio Del-Moral-Luque; Ruth Gil-Prieto; Ángel Gil-de-Miguel; Ramón Mazzuccheli-Esteban; Gil Rodríguez-Caravaca Journal: BMC Health Serv Res Date: 2020-05-04 Impact factor: 2.655